ProLynx announces preclinical results of long-acting semaglutide requiring once monthly dosing
SAN FRANCISCO, Aug. 21, 2024 (GLOBE NEWSWIRE) - ProLynx Inc. today announced the use of their technology to create a long-acting semaglutide that can be administered once monthly. The ProLynx technology involves tethering a therapeutic to hydrogel microspheres via linkers with tunable, pre-programmed release rates. Semaglutide is a peptide GLP-1 agonist that is the active ingredient in the Novo Nordisk blockbuster drugs Ozempic® and Wegovy®; Ozempic® is used to treat Type 2 diabetes, whereas Wegovy® is a higher-dose version approved for weight loss. Combined sales of these drugs reached about $20 billion in 2023, and demand exceeded supply. Semaglutide has a half-life of about 160 hours and, as with most anti-obesity peptides, must be administered once weekly.
All peptide drugs have short half-lives and require some form of half-life extension. Almost all of the current anti-obesity drugs, including semaglutide, are "lipidated" peptides – attached to a fatty acid – that require once weekly injections. The ProLynx long-acting semaglutide was targeted for once monthly administration, and pharmacokinetic experiments verified an extended half-life of about 30 days in mice. Importantly, a single injection in diet-induced obese mice showed about a 20% weight loss after 30 days, comparable to multiple injections of semaglutide over the same period.
Daniel Santi, co-founder and President of ProLynx, stated, “Our long-acting semaglutide is compelling because it uses the very same semaglutide that is already approved by the FDA and well-known to patients. The technology simply converts the once weekly drug to one that can be administered once monthly. Previously, ProLynx developed a long-acting monthly peptide GLP-1 agonist as an agent for the treatment of type-2 diabetes (Schneider et al., ACS Chem. Biol. 2017), but this is the first time we achieved this with a lipidated peptide.”
Using the same approach, ProLynx envisions converting other lipidated peptides of high current interest from once weekly to once monthly administration. Additionally, simulations indicate that the long half-lives and high potencies of some GLP-1 agonists might allow for dosing every three or more months. This could be particularly important in certain patient populations because dosing could coincide with doctor's visits.
ProLynx is a San Francisco biotechnology company developing proprietary systems to extend the half-life and improve pharmacokinetics and efficacy, while reducing toxicities of important therapies. ProLynx focuses efforts on areas of unmet needs that its technology can uniquely fill (www.ProLynxinc.com). Contact: BD@ProLynxinc.com
- FLOWER NINE“楚辞·汉光”长城大秀|谢欣晓 耀然相映 如光似火
- 黑芝麻智能招股进行中:身处热门赛道 巨大投资价值有望被激发
- 大陆人可以在香港开公司吗,香港公司注册开户多少钱
- 亚马逊海外购38女人节焕彩上线,追寻世界「春日调色盘」
- 歌手刘洋洋加入中国传统文化促进会
- 王鹤润杨幂二搭《哈尔滨一九四四》 高能对手戏引观众期待
- 【第二届】好普杯正一生命文化艺术大赛初赛获奖名单出炉啦
- 揽胜天下成为2024巴黎奥运会开幕式第一个出场的中国运动品牌
- 名品世家携汉代酱酒亮相仁怀酱酒集团产品推介会
- 京东“春晓计划”助力2024上海国际茶博会 .doc
- 北京中达寄件:携手轮滑冠军郭丹,以高铁速度共绘品牌新蓝图
- 让展会从“中国”出发到“世界各地”,不变的是文化整合的方法论
- 地夸磷索钠滴眼液上市申请 已经正式获中国国家药品监督管理局(NMPA)受理
- 东莞市仕达首饰礼品有限公司-------高端艺术珠宝首饰、五金饰品制造品牌
- 2024 年全球最富裕城市
- 望京之星|醇熟商务领域,塑造企业专属商务生活场
- 国网邵东市供电公司:靠前监督强责任 鏖战冰雪保民生
- 孙夏铃歌曲《Em Đã Biết我知道》大热 曾收获多个奖项备受好评
- 大医精诚五十载 济世立人著华章 ——记昆明卫生职业学院理事长龙正昌
- 北京石景山八大处中西医结合医院特聘专家祝艳做客《健康北京》:过敏性疾病 三分治七分养
推荐
- 透过数据看城乡居民医保“含金量” 缴费标准是否合理? 记者从国家医保局了解到,近期,全国大部分地区 资讯
- 男子“机闹”后航班取消,同机旅客准备集体起诉 1月4日,一男子大闹飞机致航班取消的新闻登上 资讯
- 周星驰新片《少林女足》在台湾省举办海选,吸引了不少素人和足球爱好者前来参加 周星驰新片《少林女足》在台湾省举办海选,吸 资讯
- 一个“江浙沪人家的孩子已经不卷学习了”的新闻引发议论纷纷 星标★ 来源:桌子的生活观(ID:zzdshg) 没 资讯
- 私域反哺公域一周带火一家店! 三四线城市奶茶品牌茶尖尖两年时间做到GMV 资讯
- 大家一起关注新疆乌什7.1级地震救援见闻 看到热气腾腾的抓饭马上就要出锅、村里大家 资讯
- 海南大学生返校机票贵 有什么好的解决办法吗? 近日,有网友在“人民网领导留言板&rdqu 资讯
- 中央气象台连发四则气象灾害预警 暴雪橙色预警+冰冻橙色预警+大雾黄色预警+ 资讯
- 新增供热能力3200万平方米 新疆最大热电联产项目开工 昨天(26日),新疆最大的热电联产项目—&md 资讯
- 国足13次出战亚洲杯首次小组赛0进球 北京时间1月23日消息,2023亚洲杯小组 资讯